Search Results for: Q

Actuate Therapeutics Announces Pricing of Initial Public Offering

August 12, 2024 20:27 ET CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of […]

Actuate Therapeutics Announces Pricing of Initial Public Offering Read More »

Actuate Therapeutics Files Registration Statement for Initial Public Offering

May 28, 2024 07:00 ET CHICAGO and FORT WORTH, Texas, May 28, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (“Actuate”) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price

Actuate Therapeutics Files Registration Statement for Initial Public Offering Read More »

Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting

April 08, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The abstracts are

Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting Read More »

Investors

INVESTOR OVERVIEW Corporate profile Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential

Investors Read More »

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

CHICAGO, IL and FORT WORTH, TX, October 18, 2022 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.  Dr. Roger

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD Read More »

Cookie Policy

COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly

Cookie Policy Read More »

Accessibility

ACCESSIBILITY STATEMENT OUR COMMITMENT TO ACCESSIBILITY Actuate is committed to making our website accessible to everyone. We have built our website in a manner to work with assistive technologies using the Worldwide Web Consortium’s Website Content Accessibility Guidelines. Actuate continues to evaluate its website to maintain and expand its accessibility for all visitors. FEEDBACK If

Accessibility Read More »

CONTACT US

CONTACT US If you would like to partner with us, have media inquiries, or simply want to learn more, we want to hear from you. Fill out the form below to get in touch. US ADDRESS 1751 River Run, Suite 400 Fort Worth, TX 76107 EMAIL info@actuatetherapeutics.com EU ADDRESS The Black Church St. Mary’s Place

CONTACT US Read More »

CAREERS

CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by

CAREERS Read More »